Kymera Therapeutics
A clinical-stage biotechnology company developing medicines based on targeted protein degradation.
Last updated September 11, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Kymera Therapeutics describes itself as a clinical-stage biotechnology company working to reinvent the treatment of human disease through innovative, highly differentiated medicines. It is committed to advancing novel technologies such as targeted protein degradation to address previously undrugged disease-causing proteins, and states that it has built a discovery engine capable of advancing at least one new program into clinical testing every year. Its leadership team includes Founder, President & CEO Nello Mainolfi, PhD.
History
Kymera Therapeutics is a clinical-stage biotechnology company that states it is working to reinvent the treatment of human disease through innovative, highly differentiated medicines. It is committed to advancing novel technologies such as targeted protein degradation to address previously undrugged disease-causing proteins. The company states that since its founding it has built a discovery engine capable of identifying new drug candidates at an accelerated pace and advancing at least one new program into clinical testing every year. Its leadership includes Founder, President & CEO Nello Mainolfi, PhD, and Co-Founder Bruce Booth, DPhil, who serves as a board member.
Products and positioning
Clinical-stage biotechnology company focused on targeted protein degradation and first-in-class therapeutics.
Recent events
Reported
A-Alpha Bio and Kymera Therapeutics announce discovery partnership[5]
A-Alpha Bio and Kymera Therapeutics announced a partnership to discover and characterize novel pairs of E3 ubiquitin ligases and high-value therapeutic targets for the design and development of molecular glues.
Reported
Kymera appoints Juliet Williams as senior vice president, head of biology[6]
Kymera Therapeutics announced the appointment of Juliet Williams, PhD, as Senior Vice President, Head of Biology.
Sources6 sources
- 1Revolutionary Medicines Catalyzed by Protein Degradation | Kymera Therapeuticskymeratx.com
- 2Our Company | Kymera Therapeuticskymeratx.com
- 3Leadership | Kymera Therapeuticskymeratx.com
- 4Kymera Therapeuticswikidata.org
- 5A-Alpha Bio与Kymera Therapeutics宣布发现研究合作prweb.com
- 6Kymera 任命 Juliet Williams 为高级副总裁兼生物学负责人biospace.com
Cite this profile: Cite the canonical profile. /brand-wiki/kymera-therapeutics · Editorial policy · How profiles are compiled